Juno touts latest cancer drug results after rivals win FDA approval

Juno Therapeutics Inc. has announced new cancer trial results that could help the drugmaker leapfrog key competitors in the rapidly emerging cancer immunotherapy industry. Juno said the latest data from its lead product candidate, called JCAR017, are stronger than from Novartis Pharmaceuticals Corp. and Kite Pharma Inc. Both rivals recently won Food and Drug Administration approval to start selling their CAR-T (chimeric antigen receptor T cell) treatments. "There's been this odd belief that all…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news